Citations

Showing 10 of 108162 citations.

Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma
Chakrabarti, Sakti , Ahn, Daniel H. , Fruth, Briant, Hartgers, Mindy L., Wessling, Jaclynn, Walkes, Rachel L., Liu, Minetta C. , Durgin, Lori, Bekaii‐Saab, Tanios , Zemla, Tyler J, McWilliams, Robert R. , Durgin, Lori M, Mahipal, Amit , Bekaii-Saab, Tanios S , Chakrabarti, Sakti , Zemla, Tyler , Ou, Fang‐Shu , Borad, Mitesh J. , Alberts, Steven R. , Mahipal, Amit

Mayo Clinic

The Oncologist | December 11, 2019 | Volume: 25 | Issue: 5 | Pages: 380-e763

10.1634/theoncologist.2019-0874 | PMID 31826977 Get It

AbstractTrial InformationClick here to access other published clinical trials.Lessons LearnedTrifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors. FTD/TPI has an acceptable safety profile and should be studied further in patients with advanced biliary tract carcinoma after progression on standard first-line therapy.BackgroundPatients with advanced biliary tract carcinoma (BTC) refractory to first-line therapy lack an established second-line option. Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC.MethodsPatients with advanced BTC previously treated with at least one line of chemotherapy were enrolled and treated with FTD/TPI until disease progression or unacceptable toxicity. The primary endpoint target was to have at least 6 patients who were progression free and alive at 16 weeks among 25 evaluable patients. Secondary endpoints included overall survival (OS), overall response rate (ORR), progression-free survival (PFS), and toxicity.ResultsOf 27 evaluable patients, 59.3% received at least three prior lines of therapy, and 81.5% had previous exposure to fluoropyrimidine. Eight (32%, 95% confidence interval [CI], 14.9%–53.5%) patients were progression free at 16 weeks in the primary analysis population (n = 25), which met the predefined efficacy criteria. Median PFS and OS were 3.8 (95% CI, 2–5.8 months) and 6.1 (95% CI, 4.4–11.4 months) months, respectively. No objective responses were seen. There were no unexpected safety signals noted.ConclusionFTD/TPI demonstrated promising antitumor activity, with acceptable toxicity, in heavily pretreated patients with advanced BTC.
Role of the Microenvironment in Gastrointestinal Tumors
Weygant, Nathaniel , Ge, Yang , Westphalen, C. Benedikt , Ma, Wen Wee, Weygant, Nathaniel , Wee, Wen , Vega, Kenneth J.

Mayo Clinic

Journal of Oncology | December 11, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-2

10.1155/2019/2153413 | PMID 31885570 Get It

Association of Florida House Bill 21 With Postoperative Opioid Prescribing for Acute Pain at a Single Institution
Porter, Steven B. , Glasgow, Amy E. , Habermann, Elizabeth B. , Glasgow, Amy E. , Yao, Xiaoxi , Habermann, Elizabeth , Porter, Steven B , Glasgow, Amy E

Mayo Clinic

JAMA Surgery | December 11, 2019 | Volume: 155 | Issue: 3 | Pages: 263

10.1001/jamasurg.2019.4913 | PMID 31825491 Get It

The role of geriatric palliative care in hospitalized older adults
Santivasi, Wil L. , Partain, Daniel K. , Whitford, Kevin J. , Partain, Daniel K

Mayo Clinic

Hospital Practice | December 11, 2019 | Volume: 48 | Issue: sup1 | Pages: 37-47

10.1080/21548331.2019.1703707 | PMID 31825689 Get It

Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations
Kotwal, Anupam , Kumar, Rajiv , Murthy, Vishakantha , Schultz‐Rogers, Laura , Zimmermann, Michael T. , Lanpher, Brendan C. , Stabach, Paul R., Klee, Eric W. , Braddock, Demetrios T. , Wermers, Robert A. , Schultz-Rogers, Laura, Lanpher, Brendan, Klee, Eric, Braddock, Demetrios T , Kudva, Yogish C , Zimmermann, Michael T , Kumar, Rajiv , Ferrer, Alejandro , Singh, Ravinder , Savill, Kristin M. Zimmerman

Mayo Clinic

Journal of Bone and Mineral Research | December 11, 2019 | Volume: 35 | Issue: 4 | Pages: 662-670

10.1002/jbmr.3938 | PMID 31826312 Get It

ABSTRACT Inactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal-recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54-year-old female with biallelic mutation of ENPP1, c.323G > T; p.Cys108Phe and c.1441C > T; p.Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation, which was not previously reported, was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multigland parathyroidectomy, increased carotid intima-media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C-terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism, which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation. © 2019 American Society for Bone and Mineral Research.
Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q
Musolf, Anthony M. , Moiz, Bilal A., Sun, Haiming , Pikielny, Claudio W. , Bossé, Yohan , Mandal, Diptasri , Andrade, Mariza de , Gaba, Colette , Li, Yafang , You, Ming , Govindan, Ramaswamy , Wilson, Richard K., Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Bailey‐Wilson, Joan E. , de Andrade, Mariza , Wilson, Richard K , Amos, Christopher I , Bossé, Yohan , Pinney, Susan M , Govindan, Ramaswamy , Yang, Ping , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 11, 2019 | Volume: 29 | Issue: 2 | Pages: 434-442

10.1158/1055-9965.epi-19-0887 | PMID 31826912 Get It

Abstract Background: Lung cancer kills more people than any other cancer in the United States. In addition to environmental factors, lung cancer has genetic risk factors as well, though the genetic etiology is still not well understood. We have performed whole exome sequencing on 262 individuals from 28 extended families with a family history of lung cancer. Methods: Parametric genetic linkage analysis was performed on these samples using two distinct analyses—the lung cancer only (LCO) analysis, where only patients with lung cancer were coded as affected, and the all aggregated cancers (AAC) analysis, where other cancers seen in the pedigree were coded as affected. Results: The AAC analysis yielded a genome-wide significant result at rs61943670 in POLR3B at 12q23.3. POLR3B has been implicated somatically in lung cancer, but this germline finding is novel and is a significant expression quantitative trait locus in lung tissue. Interesting genome-wide suggestive haplotypes were also found within individual families, particularly near SSPO at 7p36.1 in one family and a large linked haplotype spanning 4q21.3-28.3 in a different family. The 4q haplotype contains potential causal rare variants in DSPP at 4q22.1 and PTPN13 at 4q21.3. Conclusions: Regions on 12q, 7p, and 4q are linked to increased cancer risk in highly aggregated lung cancer families, 12q across families and 7p and 4q within a single family. POLR3B, SSPO, DSPP, and PTPN13 are currently the best candidate genes. Impact: Functional work on these genes is planned for future studies and if confirmed would lead to potential biomarkers for risk in cancer.
Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)
Kashou, Anthony H. , Noseworthy, Peter A.

Mayo Clinic

Expert Opinion on Investigational Drugs | December 11, 2019 | Volume: 29 | Issue: 1 | Pages: 1-4

10.1080/13543784.2020.1703180 | PMID 31825681 Get It

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus , Panina, Ekaterina, Gambietz, Agnes, Larson, Richard A. , Prior, Thomas W., Marcucci, Guido , Krauter, Jürgen, Heuser, Michael , Ottone, Tiziana , Nomdedéu, Josep , Mandrekar, Sumithra J. , Klisovic, Rebecca B. , Wei, Andrew H. , Sierra, Jorge , Sanz, Miguel Á. , Brandwein, Joseph , Witte, Théo de , Niederwieser, Dietger , Appelbaum, Frederick R. , Medeiros, Bruno C. , Tallman, Martin S. , Schlenk, Richard F. , Ganser, Arnold , Ehninger, Gerhard , Gathmann, Insa, Benner, Axel , Pallaud, Céline , Stone, Richard M. , Bloomfield, Clara D. , Larson, Richard A , Wei, Andrew H , Jones, Dan M. , Voso, Maria Teresa , Jansen, Joop H. , Serve, Hubert L. , Amadori, Sergio , Döhner, Hartmut

Mayo Clinic

Blood | December 11, 2019 | Volume: 135 | Issue: 5 | Pages: 371-380

10.1182/blood.2019002697 | PMID 31826241 Get It

Abstract Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (≥0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 NPM1/FLT3-ITD genotypes differed significantly with regard to clinical and concurrent genetic features. Complete ELN risk categorization could be done in 318 of 549 trial patients with FLT3-ITD AML. Significant factors for response after 1 or 2 induction cycles were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence. Overall survival (OS) differed significantly among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001). A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors. In this model, there was a consistent beneficial effect of midostaurin across ELN risk groups.
Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take?
Moulder, Magali P. Disdier , Hendricks, Abby K. , Ou, Narith N., Disdier Moulder, Magali P A

Mayo Clinic

Clinical Cardiology | December 11, 2019 | Volume: 43 | Issue: 2 | Pages: 137-144

10.1002/clc.23304 | PMID 31825133 Get It

AbstractBackgroundPolypharmacy in older adults leads to increased risks of side effects and drug‐drug interactions, affecting their health outcomes and quality of life. Deprescribing, the act of simplifying medication regimens, is challenging due to the lack of consensus guidelines.HypothesisTo offer some guidance on managing medication regimens for older cardiovascular patients.MethodsWe reviewed the most recent pertinent guidelines and literature.ResultsThis review provides practical considerations for appropriate prescribing in the older population with cardiovascular disease in order to strike a balance between unnecessary or harmful medications and therapies with proven long‐term benefits.ConclusionOn‐going dialogue between healthcare providers and patients allows close monitoring of medication effectiveness and prevention of side effects. Medication regimens require individualization, as patients' goals of care change with advancing age.